Purinergic P2 Receptor Antagonists
"Purinergic P2 Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that bind to and block the stimulation of PURINERGIC P2 RECEPTORS.
| Descriptor ID |
D058919
|
| MeSH Number(s) |
D27.505.519.625.725.400.200 D27.505.696.577.725.400.200
|
| Concept/Terms |
Purinergic P2 Receptor Antagonists- Purinergic P2 Receptor Antagonists
- Purinergic P2 Receptor Blockers
- P2 Purinoceptor Blockers
- Blockers, P2 Purinoceptor
- Purinoceptor Blockers, P2
- P2 Purinoceptor Antagonists
- Antagonists, P2 Purinoceptor
- Purinoceptor Antagonists, P2
|
Below are MeSH descriptors whose meaning is more general than "Purinergic P2 Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Purinergic P2 Receptor Antagonists".
This graph shows the total number of publications written about "Purinergic P2 Receptor Antagonists" by people in this website by year, and whether "Purinergic P2 Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 2 | 0 | 2 |
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Purinergic P2 Receptor Antagonists" by people in Profiles.
-
Jakubowski JA, Zhou C, Small DS, Winters KJ, Lachno DR, Frelinger AL, Howard J, Mant TG, Jurcevic S, Payne CD. A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity. Br J Clin Pharmacol. 2013 Jun; 75(6):1433-44.
-
Frelinger AL, Michelson AD, Wiviott SD, Trenk D, Neumann FJ, Miller DL, Jakubowski JA, Costigan TM, McCabe CH, Antman EM, Braunwald E. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost. 2011 Aug; 106(2):219-26.
-
Chang H, Yanachkov IB, Michelson AD, Li Y, Barnard MR, Wright GE, Frelinger AL. Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. Thromb Res. 2010 Feb; 125(2):159-65.
-
Michelson AD. New P2Y12 antagonists. Curr Opin Hematol. 2009 Sep; 16(5):371-7.
-
Faxon DP, Freedman JE. Facts and controversies of aspirin and clopidogrel therapy. Am Heart J. 2009 Mar; 157(3):412-22.
-
Michelson AD. P2Y12 antagonism: promises and challenges. Arterioscler Thromb Vasc Biol. 2008 Mar; 28(3):s33-8.
-
Frelinger AL, Jakubowski JA, Li Y, Barnard MR, Linden MD, Tarnow I, Fox ML, Sugidachi A, Winters KJ, Furman MI, Michelson AD. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost. 2008 02; 6(2):359-65.
-
Frelinger AL, Jakubowski JA, Li Y, Barnard MR, Fox ML, Linden MD, Sugidachi A, Winters KJ, Furman MI, Michelson AD. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thromb Haemost. 2007 Jul; 98(1):192-200.
-
Dalal AR, D'Souza S, Shulman MS. Brief review: coronary drug-eluting stents and anesthesia. Can J Anaesth. 2006 Dec; 53(12):1230-43.